Latest News - Retina

Monday, March 20, 2017 | Clinical Trials, Retina

NightstaRx Commences First Phase 1/2 Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa

NightstaRx, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, today announces that the company has commenced enrolling and dosing subjects in a p…

Read the full story

Friday, March 17, 2017 | Earnings & Financials, Retina, Aerpio Therapeutics

Aerpio Pharmaceuticals Raises $40 Million

Aerpio Pharmaceuticals, a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced the successful completion of its reverse merger transaction with Aerpi…

Read the full story

Monday, March 13, 2017 | Clinical Trials, Retina

BioTime Expands OpRegen Clinical Trial in Dry AMD With Opening of First US Sites

BioTime announced the expansion of its ongoing phase 1/2a clinical trial for OpRegen in the advanced dry form age-related macular degeneration (AMD) by naming the first two sites that will treat patie…

Read the full story

Thursday, February 16, 2017 | Acquisitions/Mergers, Retina

BioTime Expands Ophthalmology Portfolio With Global In-Licensing Agreement for Next-Generation Retinal Disease Therapy From University of Pittsburgh

BioTime announced that the company has obtained a worldwide license to intellectual property (IP) assets from University of Pittsburgh. The technology was developed in part in collaboration with BioTi…

Read the full story

Tuesday, February 14, 2017 | Earnings & Financials, Retina, Pixium Vision

Pixium Vision Receives NUB Innovation Reimbursement Status-1 for 150 Electrode IRIS II Bionic System in Germany

Pixium Vision announced that the German Institute for the Hospital Remuneration System (InEK) has granted NUB (Neue Untersuchungs- und Behandlungsmethoden) Status-1 for IRIS II, Pixium Vision’s …

Read the full story

Wednesday, February 08, 2017 | Medical Studies, Retina

ProtoKinetix Updates Testing Progress on Neuronal Retinal Cells in Living Tissue for the Treatment of Macular Degeneration

ProtoKinetix updated its stockholders on the testing of neuronal retinal cells in living tissue at the University of British Columbia (“UBC”) under the guidance of Kevin Gregory-Evans…

Read the full story

Friday, February 03, 2017 | Medical Studies, Retina, AMD

Dexamethasone Implant With Anti-VEGF Explored for Wet AMD

Used in combination with antivascular endothelial growth factor (anti-VEGF) therapy, dexamethasone implants (0.7 mg Ozurdex, Allergan) may help some patients with neovascular age-related macular degen…

Read the full story

Thursday, January 26, 2017 | Product Demos, Retina

For the First Time, Surgical Eye Robot Performs Precision Injection in Patient with Retinal Vein Occlusion

Surgeons at the University Hospitals Leuven in Belgium were the first to operate using a surgical robot on a patient with retinal vein occlusion (RVO). Operated by an eye surgeon, the robot uses a nee…

Read the full story

Monday, December 12, 2016 | Clinical Trials, Retina, Ophthotech

Ophthotech Fails Phase 3 Trials of Fovista in Wet Age-Related Macular Degeneration

Ophthotech announced that the prespecified primary endpoint of mean change in visual acuity at 12 months was not achieved in its two pivotal phase 3 clinical trials investigating the superio…

Read the full story

Thursday, December 01, 2016 | Retina

Google AI Matches Diabetic Retinopathy Screens

Ophthalmologists do not have to worry just yet, but data from a new machine learning study suggest computers will be able to screen for diabetic retinopathy with similar accuracy, and better cost-effe…

Read the full story

Thursday, November 17, 2016 | Retina

Assessing Uveitis: Beyond Vitreous Haze

The presentations of uveitis are as varied as the brands of artificial tears at your local drug store. A case of panuevitis can just as easily present with choroidal thickening and headaches as it can…

Read the full story

Friday, October 14, 2016 | Retina, Novartis

Lucentis Recommended by CHMP for EU Approval in Sixth Indication for the Treatment of Visually Impaired Patients

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lucentis (ranibizumab) to treat patients with visual impairment due to choroidal ne…

Read the full story

Friday, October 14, 2016 | Retina

Spark Therapeutics Launches Initiative to Improve Access to Genetic Testing for Inherited Retinal Diseases

Spark Therapeutics will provide physicians and eligible patients access to genetic testing and counseling for more than 30 genes linked to certain forms of inherited retinal diseases (IRDs), a group o…

Read the full story

Thursday, October 13, 2016 | Partnerships, Retina, Ocular Therapeutix, Regeneron Pharmaceuticals

Ocular Therapeutix and Regeneron Collaborate to Develop a Sustained-Release Formulation of Aflibercept for Wet AMD and Other Retinal Diseases

In a deal that could be worth more than $300 million, Ocular Therapeutix announced that it has entered into a strategic collaboration, option, and license agreement with Regeneron Pharmaceuticals to c…

Read the full story

Thursday, October 13, 2016 | Clinical Trials, Retina, Allegro Ophthalmics

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2B Trial Evaluating Luminate in Patients with Diabetic Macular Edema

Allegro Ophthalmics announced that the DEL MAR phase 2b clinical trial evaluating Luminate (ALG-1001) in 136 patients with diabetic macular edema (DME) met its primary and secondary endpoints, demonst…

Read the full story
Load More